recombinant drugs to 2020   Recombinant Drugs to 2020 • Published February 2017 •  Catalog no. RDM259K17  •  Price US $3,850


In recent years, the number of recombinant drugs – including engineered biological drugs in development – has increased significantly. The pace of this growth is encouraging suppliers to view competitors in new ways. Cooperation between and among drug developers and drug producers is occurring much earlier in the drug development cycle, allowing participants to improve supply chains and time-to-market. The result is a rapidly growing market sector that is changing disease therapeutics on a global scale. This report examines FDA and EMA-approved biological drugs and their position and potential in a dozen major disease segments – markets with important implications for drug developers, contract and supply chain partners and infrastructure participants. Growth prospects for key biological drug therapeutic segments will vary over the forecast period covered in this analysis, influenced by demographic, socioeconomic and competitive factors.

Bar_Graph   Report Brochure (Download PDF)

Blue document    Report Order Form (Download PDF)


Recombinant Drugs to 2020 – What You Will Learn

• What are the currently approved biological drugs; their host system, indication(s)?
• What are the key market segments for biological drugs; what is the competitive picture for each segment?
• What are the drug classes, therapeutic classes and market segments that comprise the global market for biological drugs?
• What are the supply chain dynamics of biological drug sourcing and commercialization?
• What is the revenue picture for each drug/class? What will it look like in 2020?
• Who are the leading biological drug suppliers, and what are the key collaborations in the sourcing cycle?
• What is the drug landscape for key market segments? What is the market share? What is the size?


Recombinant Drugs to 2020 – Summary of Contents

Executive Summary

Recombinant Drug Market Dynamics

The Biological Therapeutics Market Space
Clinical Trials and Drug Approvals
The Competitive Landscape
Demographics, Managed Care and Growth
Demand Drivers and Treatment Factors
Disease Type and Severity
Self-Treatment
Administration & Packaging
Reimbursement & Managed Care
Recombinant Drug Sourcing
Sourcing by Company
Sourcing by Country/Region
Sourcing Relationships

Product Technology Factors

Therapeutic Targets
Receptors, Inhibitors and Blockers
PEGylated Formulations

Recombinant Drug Analysis

FDA-Approved Drugs
EU-Approved Drugs
Approved Biosimilars

Recombinant Drug Market Analysis

Antihemophilic Factors
Antineoplastics
Colony Stimulating Factors
Enzyme Therapy
Erythropoiesis-stimulating Proteins
Follicle Stimulating Hormones
Glycemic Control
Growth Hormones
Non-TNF Immune Modulators
TNF Inhibitors
VEGF Inhibitors

Market Factors

Regulatory Issues
Biosimilars
Healthcare Economics

Company Profiles